Artelo Biosciences, Inc. (ARTL): Price and Financial Metrics
ARTL Price/Volume Stats
| Current price | $0.95 | 52-week high | $1.75 |
| Prev. close | $0.95 | 52-week low | $0.91 |
| Day low | $0.91 | Volume | 35,300 |
| Day high | $0.95 | Avg. volume | 35,137 |
| 50-day MA | $1.13 | Dividend yield | N/A |
| 200-day MA | $1.28 | Market Cap | 3.06M |
ARTL Stock Price Chart Interactive Chart >
Artelo Biosciences, Inc. (ARTL) Company Bio
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was founded in 2011 and is headquartered in La Jolla, California.
ARTL Price Returns
| 1-mo | -15.93% |
| 3-mo | -10.38% |
| 6-mo | -24.30% |
| 1-year | -29.63% |
| 3-year | -89.60% |
| 5-year | -97.49% |
| YTD | -32.14% |
| 2023 | -51.56% |
| 2022 | -62.88% |
| 2021 | -28.90% |
| 2020 | -72.96% |
| 2019 | -60.87% |
Loading social stream, please wait...